Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST6GAL1 | P15907 | 7/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | TYMP | P19971 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5150771 | 0.88 | NT5E (0.51) | ST6GAL1NT5ELMNATHRBMTOR | |
| SCHEMBL5859682 | 0.85 | POLB (0.41) | ST6GAL1LMNA | |
| SCHEMBL10430326 | 0.85 | ST6GAL1 (0.41) | ST6GAL1NT5ELMNATHRBMTOR | |
| SCHEMBL1317526 | 0.82 | NT5E (0.45) | ST6GAL1NT5ELMNATHRBMTOR | |
| SCHEMBL1318619 | 0.82 | NT5E (0.45) | ST6GAL1NT5ELMNATHRBMTOR | |
| SCHEMBL384131 | 0.81 | ST6GAL1 (0.39) | ST6GAL1NT5ELMNATHRBMTOR | |
| SCHEMBL9404664 | 0.80 | NT5E (0.52) | ST6GAL1NT5ELMNATHRBMTOR | |
| SCHEMBL8433551 | 0.80 | ADORA1 (0.51) | TYMP | |
| SCHEMBL8598173 | 0.80 | NT5E (0.43) | ST6GAL1NT5ELMNATHRBMTOR | |
| SCHEMBL17599856 | 0.79 | ST6GAL1 (0.42) | ST6GAL1NT5ELMNATHRBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070218490-A1 | NUCLEIC ACID MONOMERS WITH 2'-CHEMICAL MOIETIES | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007106907-A2 | NUCLEIC ACID MONOMERS WITH 2'-CHEMICAL MOIETIES | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070218490-A1 | NUCLEIC ACID MONOMERS WITH 2'-CHEMICAL MOIETIES | POLRMT, RNGTT, POLM | ST6GAL1 2390/4885NT5E 82/4885LMNA 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.